A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Eilean Therapeutics
Incyte Corporation
Incyte Corporation
Incyte Corporation
Hangzhou GluBio Pharmaceutical Co., Ltd.
AbbVie
Astex Pharmaceuticals, Inc.
Novartis
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Exelixis